BR112023022050A2 - Agonistas do receptor de orexina e usos destes - Google Patents
Agonistas do receptor de orexina e usos destesInfo
- Publication number
- BR112023022050A2 BR112023022050A2 BR112023022050A BR112023022050A BR112023022050A2 BR 112023022050 A2 BR112023022050 A2 BR 112023022050A2 BR 112023022050 A BR112023022050 A BR 112023022050A BR 112023022050 A BR112023022050 A BR 112023022050A BR 112023022050 A2 BR112023022050 A2 BR 112023022050A2
- Authority
- BR
- Brazil
- Prior art keywords
- receptor agonists
- orexin receptor
- formula
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 229940127340 Orexin Receptor Agonists Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000002512 Orexin Human genes 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 108060005714 orexin Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163183321P | 2021-05-03 | 2021-05-03 | |
| PCT/EP2022/061851 WO2022233872A1 (en) | 2021-05-03 | 2022-05-03 | Orexin receptor agonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023022050A2 true BR112023022050A2 (pt) | 2023-12-26 |
Family
ID=81940742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023022050A BR112023022050A2 (pt) | 2021-05-03 | 2022-05-03 | Agonistas do receptor de orexina e usos destes |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240254143A1 (https=) |
| EP (1) | EP4334323A1 (https=) |
| JP (1) | JP2024516033A (https=) |
| KR (1) | KR20240004802A (https=) |
| CN (1) | CN117616030A (https=) |
| AU (1) | AU2022269811A1 (https=) |
| BR (1) | BR112023022050A2 (https=) |
| CA (1) | CA3217403A1 (https=) |
| IL (1) | IL308099A (https=) |
| MX (1) | MX2023012971A (https=) |
| TW (1) | TW202309051A (https=) |
| WO (1) | WO2022233872A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI4065585T3 (fi) | 2019-11-25 | 2025-09-26 | Alkermes Inc | Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| US12006330B2 (en) | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| WO2023081094A1 (en) * | 2021-11-04 | 2023-05-11 | University Of Washington | Novel spirocyclic compounds as klhdc2 ligands |
| EP4658660A1 (en) | 2023-01-31 | 2025-12-10 | Jazz Pharmaceuticals Ireland Limited | Macrocyclic orexin receptor agonists and uses thereof |
| CN116478076A (zh) * | 2023-04-26 | 2023-07-25 | 南京优氟医药科技有限公司 | 一种(2s,4s)-1-叔丁氧羰基-2-(二氟甲基)-4-羟基吡咯烷的制备方法 |
| WO2025124698A1 (en) | 2023-12-12 | 2025-06-19 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| TW202542165A (zh) | 2023-12-19 | 2025-11-01 | 瑞士商愛杜西亞製藥有限公司 | 大環食慾素激動劑 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69318854T2 (de) * | 1993-03-04 | 1998-10-08 | Pfizer | Spiroazacyclischderivate als substanz p antagonisten |
| DE69923744T2 (de) * | 1998-10-23 | 2006-02-23 | Pfizer Inc. | 1,3,8-Triazaspiro[4,5] decanon Verbindungen als orl1-receptor Agonisten |
| WO2011076747A1 (en) * | 2009-12-21 | 2011-06-30 | Novartis Ag | Diaza-spiro[5.5]undecanes as orexin receptor antagonists |
| US20120101110A1 (en) * | 2010-10-26 | 2012-04-26 | Sangamesh Badiger | Diaza-spiro[5.5]undecanes |
| PL3411358T3 (pl) * | 2016-02-04 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Podstawiony związek piperydynowy i jego zastosowanie |
| JP7413261B2 (ja) * | 2018-06-29 | 2024-01-15 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| US11098029B2 (en) * | 2019-02-13 | 2021-08-24 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
-
2022
- 2022-05-03 KR KR1020237041381A patent/KR20240004802A/ko active Pending
- 2022-05-03 MX MX2023012971A patent/MX2023012971A/es unknown
- 2022-05-03 CN CN202280045968.9A patent/CN117616030A/zh active Pending
- 2022-05-03 WO PCT/EP2022/061851 patent/WO2022233872A1/en not_active Ceased
- 2022-05-03 JP JP2023567888A patent/JP2024516033A/ja active Pending
- 2022-05-03 EP EP22727800.9A patent/EP4334323A1/en active Pending
- 2022-05-03 US US18/558,245 patent/US20240254143A1/en active Pending
- 2022-05-03 AU AU2022269811A patent/AU2022269811A1/en active Pending
- 2022-05-03 TW TW111116714A patent/TW202309051A/zh unknown
- 2022-05-03 IL IL308099A patent/IL308099A/en unknown
- 2022-05-03 CA CA3217403A patent/CA3217403A1/en active Pending
- 2022-05-03 BR BR112023022050A patent/BR112023022050A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023012971A (es) | 2024-01-16 |
| JP2024516033A (ja) | 2024-04-11 |
| AU2022269811A1 (en) | 2023-11-16 |
| US20240254143A1 (en) | 2024-08-01 |
| EP4334323A1 (en) | 2024-03-13 |
| CN117616030A (zh) | 2024-02-27 |
| KR20240004802A (ko) | 2024-01-11 |
| WO2022233872A1 (en) | 2022-11-10 |
| TW202309051A (zh) | 2023-03-01 |
| IL308099A (en) | 2023-12-01 |
| CA3217403A1 (en) | 2022-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023022050A2 (pt) | Agonistas do receptor de orexina e usos destes | |
| BR112022010254A2 (pt) | Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio | |
| CO2021013927A2 (es) | Protacs que degradan el receptor de estrógeno | |
| BR112021019256A2 (pt) | Moduladores de receptor x4 de proteína g relacionado a mas e produtos e métodos relacionados | |
| AR046308A1 (es) | Derivados amida | |
| MA39317A1 (fr) | Dérivés de nucléosides à substitution 4'-difluorométhyle utilisés en tant qu'inhibiteurs de la réplication de l'arn du virus de la grippe | |
| DOP2021000148A (es) | Compuestos moduladores de fxr (nr1h4) | |
| CR20190261A (es) | Inhibidores de la tirosina quinasa de bruton | |
| BRPI0917661B8 (pt) | produto, composição farmacêutica e uso da combinação de macitentan com um composto que é dotado de propriedades agonistas do receptor de prostaciclina | |
| MY208400A (en) | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (ror) and pharmaceutical uses thereof | |
| PY1978496A (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| BR112023025599A2 (pt) | Ativadores de dimetoxifenilalquilamina de receptores de serotonina. | |
| BR112023015721A2 (pt) | Derivados tricíclicos úteis como inibidores de parp7 | |
| BR112021011325A2 (pt) | Derivados de rapamicina | |
| AR117844A1 (es) | Derivados de tiazolopiridina como antagonistas del receptor de adenosina | |
| MX2022011712A (es) | Moduladores de receptor x4 de proteina g relacionado con mas y productos y metodos relacionados. | |
| MA41337A (fr) | Dérivés de l'hydroxyalkyl pipérazine utilisés comme modulateurs du récepteur cxcr3 | |
| BR112023025396A2 (pt) | Compostos de 3-pirrolilsulfonamida como antagonistas de gpr17 | |
| MX2021012248A (es) | Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos. | |
| BR112022008183A2 (pt) | Formas de sal de um receptor de c5a de componente do complemento | |
| BR112021002565A8 (pt) | Composto, sal farmaceuticamente aceitável, tautômero ou estereoisômero do mesmo, composição farmacêutica, processo para a síntese e uso do dito composto | |
| PY2221203A (es) | Derivados de ciclobutilo 1,3-sustituidos y sus usos | |
| MX2020008523A (es) | Compuesto que tiene actividad agonista del receptor esfingosina-1-fosfato [(2s,3r,4e)-2-amino-3-hidroxioctadec-4-enil- 1-fosfato (s1p5). | |
| BR112022007238A2 (pt) | Compostos modificadores derivados de anel de quatro membros, métodos para preparar os referidos compostos, composição e uso | |
| JOP20220084A1 (ar) | مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 |